Efficacy and Safety of Patients with Non-small Cell Lung Cancer Treated with Anlotinib Combined with Cinobufagin
Objective To analyze the efficacy of anlotinib combined with cinobufagin in the treatment of non-small cell lung cancer(NSCLC).Methods A total of 109 NSCLC patients admitted to the Second People's Hospital of Changshu City from January 2020 to March 2023 were selected as the study objects,and were divided into control group(n=54)and study group(n=55)by random number table method.The control group was given antirotinib com-bined with docetaxel injection chemotherapy,and the study group was given antirotinib combined with cinobufagin tab-lets.Symptom relief,tumor marker level and incidence of adverse reactions were compared between the two groups.Results The symptom remission rate of the study group was higher than that of the control group,and the level of tu-mor markers were lower than those of the control group,and the differences were statistically significant(all P<0.05).The adverse reaction rate in the study group(1.82%)was lower than that in the control group(11.11%),and the differ-ence was statistically significant(χ2=3.916,P<0.05).Conclusion The combined treatment of anlotinib and cinobufa-gin has a significant effect on NSCLC,can promote disease remission and reduce the level of tumor markers,and has a low risk of toxic and side effects,providing an effective treatment plan for NSCLC.
NETL
NSTL
万方数据
